Fusion Antibodies PLC
LSE:FAB
Fusion Antibodies PLC
Accounts Payable
Fusion Antibodies PLC
Accounts Payable Peer Comparison
Competitive Accounts Payable Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Fusion Antibodies PLC
LSE:FAB
|
Accounts Payable
£537k
|
CAGR 3-Years
-4%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
Oxford Nanopore Technologies PLC
LSE:ONT
|
Accounts Payable
£78.4m
|
CAGR 3-Years
36%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
O
|
Open Orphan PLC
LSE:ORPH
|
Accounts Payable
£2.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Diaceutics PLC
LSE:DXRX
|
Accounts Payable
£759k
|
CAGR 3-Years
38%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
Ergomed PLC
LSE:ERGO
|
Accounts Payable
£4.3m
|
CAGR 3-Years
23%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
hVIVO PLC
LSE:HVO
|
Accounts Payable
£34.2m
|
CAGR 3-Years
17%
|
CAGR 5-Years
72%
|
CAGR 10-Years
55%
|
See Also
What is Fusion Antibodies PLC's Accounts Payable?
Accounts Payable
537k
GBP
Based on the financial report for Sep 30, 2023, Fusion Antibodies PLC's Accounts Payable amounts to 537k GBP.
What is Fusion Antibodies PLC's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
1%
Over the last year, the Accounts Payable growth was -49%. The average annual Accounts Payable growth rates for Fusion Antibodies PLC have been -4% over the past three years , 1% over the past five years .